HopeStage
Back to all studies
CompletedNCT04232644

ADAIR: Safety and Abuse Potential of a Deterrent Medicine

About this titleRead the official source — NCT04232644
Medication studyAges 18–55CanadaADHD
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 55 years.

Listed locations
TorontoSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 27, 2019
Recruitment status
Completed
Enrollment listed in the registry
16
Sponsor
Vallon Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Canada
Age range
From 18 Years to 55 Years
Official registry ID
NCT04232644
Official title
Show the full official title

A Pilot, Randomized, Double-Blind, Active-Controlled, 2-Treatment, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Abuse Liability of Dextroamphetamine Sulfate From an Abuse-Deterrent Immediate-Release Formulation (ADAIR)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Vallon Pharmaceuticals, Inc.

Did this study involve medication?

Yes. The study involved medication, including ADAIR 10mg IR capsules and Crushed d-amphetamine sulfate IR tablets.

Who was this study for?

Listed age limits: 18 years to 55 years.

Want to explore more studies?

Explore studies